Before the use of rituximab, the strongest accepted evidence for an association between B-cells and rheumatoid arthritis (RA) was that clinical disease was associated with serum autoantibodies. The ability to remove B-cells with rituximab has also revealed the relative importance of the different immunological parameters that underlie the clinical symptoms of RA. Geraldine Cambridge, also known as Jo Cambridge, is Principal Research Fellow, Inflammation, Division of Medicine, Faculty of Medical Sciences, University College London in the United Kingdom.
Image courtesy of interviewee
